Immuneering Corporation Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-06-05: Study NCT07562152; Company role Lead sponsor; Phase Phase 3; Status Recruiting.
- 2024-02-27: Study NCT06208124; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Completed.
- 2022-10-31: Study NCT05585320; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Active not recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-06-05 | NCT07562152 Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Lead sponsor | Phase 3 | Recruiting | Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma | 510 | 2029-02 |
| 2024-02-27 | NCT06208124 A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Lead sponsor | Phase 1, Phase 2 | Completed | Advanced Solid Tumor (Phase 1); Pancreas Adenocarcinoma; Non-small Cell Lung Cancer; Malignant Melanoma (Cutaneous) | 30 | 2025-04-30 |
| 2022-10-31 | NCT05585320 A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | Lead sponsor | Phase 1, Phase 2 | Active not recruiting | Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC) | 209 | 2027-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |